# GLP-1 Drugs in Teenagers: What 18 Trials Show

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-19 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/glp1-drugs-in-teenagers

> Eighteen randomized trials in 1,402 children and adolescents with obesity, prediabetes or type 2 diabetes found improvements across every metabolic measure. Weight fell 3.02 kg more than on placebo, and the median treatment duration across all of them was half a year.

## Key points

- 18 trials, 1,402 young people with obesity, prediabetes or type 2 diabetes: improvements in weight, BMI, HbA1c, glucose and blood pressure.
- Weight fell 3.02 kg more than on placebo, far from the fifth of body weight adults read about.
- Median treatment duration across every trial: 0.51 years.
- No significant difference in suicidal ideation or behaviors, on short follow-up.

[The evidence for GLP-1 drugs in children and adolescents](https://glpwatchdog.org/research/lists/top-glp1-adolescent-studies) now runs to 18 randomized trials and 1,402 participants with obesity, prediabetes or type 2 diabetes, and the results are consistently positive across every metabolic measure.[1] Two numbers deserve to sit beside them: mean weight loss was **3.02 kg** more than on placebo, and the median treatment duration across all those trials was **half a year**.

## What the trials found

*Pooled results from 18 randomized trials in children and adolescents. Mean age 13.7 years, range 6 to 17.*

| Outcome | Change against placebo |
| --- | --- |
| Body weight | −3.02 kg (95% CI −4.98 to −1.06) |
| BMI | −1.45 (95% CI −2.40 to −0.49) |
| BMI standard deviation score | −0.20 (95% CI −0.36 to −0.05) |
| BMI percentile | −7.24% (95% CI −12.97 to −1.51) |
| HbA1c | −0.44% (95% CI −0.68 to −0.21) |
| Fasting glucose | −9.92 mg/dL (95% CI −16.20 to −3.64) |
| Systolic blood pressure | −2.73 mm Hg (95% CI −4.04 to −1.43) |

Every one of those is a real improvement with a confidence interval clear of zero. Gastrointestinal adverse events increased, which is expected. And on suicidal ideation or behaviors, the outcome that frightens parents most, there was no significant difference.[1]

## The weight number is much smaller than adults see

Three kilos is not what most people expect from a class of drugs discussed in terms of losing a fifth of your body weight. The gap has several explanations. The pooled trials include older and weaker drugs alongside newer ones, follow-up is short, and a growing child’s weight is not a fixed target the way an adult’s is. That last point is why BMI percentile and BMI standard deviation score are the more meaningful rows.

> Against placebo, the pooled weight difference was about three kilos, for a class of drugs discussed in terms of losing a fifth of body weight.

That does not make the result unimportant. A 7.24% drop in BMI percentile and a blood pressure reduction in a thirteen-year-old are meaningful over a lifetime, as is anything that lowers the insulin resistance behind signs such as [acanthosis nigricans](https://glpwatchdog.org/research/acanthosis-nigricans-and-weight-loss). It does mean that expectations set by adult coverage do not apply.

## Six months is the whole evidence base

The median treatment duration across these trials was 0.51 years, with an interquartile range of three months to one year.[1] This matters more here than in almost any other population.

- **A child starting at 13 could be on treatment for decades.** Six months of evidence is a thin basis for that.
- **Puberty is a developmental window**, and effects on growth, bone accrual and pubertal timing need years to observe, not months.
- **The reassuring psychiatric finding carries the same limit.** The authors say directly that the data covered a relatively short follow-up.
- **Nothing here speaks to what happens on stopping**, which in adults means most of the weight returning. In a growing child that question has no adult analog at all.

> **This is not an argument against treating children.** Severe obesity in adolescence carries its own well-documented trajectory, and doing nothing is also a decision with consequences. It is an argument for knowing that the evidence supporting the decision is six months deep, and for hearing that from someone other than a company.

A separate analysis of STEP TEENS reports what happened to insulin resistance, liver enzymes and lipids in that trial’s participants (see [what changed in the teenagers’ bloodwork](https://glpwatchdog.org/research/what-changed-in-the-teenagers-bloodwork)). Those results are encouraging, but every one of them is a surrogate marker.

## What a parent should ask

1. **Which drug, and is it approved for this age?** Approval in adolescents is drug-specific and narrower than adult approval. In type 2 diabetes, tirzepatide has been [tested in children aged 10 to 17](https://glpwatchdog.org/research/tirzepatide-in-ten-to-seventeen-year-olds).
2. **What is being measured?** BMI percentile and standard deviation score describe a growing child; kilograms do not.
3. **What is the plan for stopping, or not stopping?** Ask it at the start rather than at year three.
4. **Who is monitoring growth and puberty?** This belongs with a pediatric specialist, not a telehealth intake (see [what makes a prescription legitimate](https://glpwatchdog.org/research/what-makes-a-telehealth-glp1-prescription-legitimate)).
5. **What happens to eating behavior?** Our [eating disorders article](https://glpwatchdog.org/research/glp1-and-eating-disorders) covers screening, which matters more in adolescence than at any other age.

## Frequently asked questions

### Do GLP-1 drugs work in children and adolescents?

Yes, on every measure tested. A meta-analysis of 18 randomized trials in 1,402 participants found improvements in weight, BMI, BMI percentile, HbA1c, fasting glucose and blood pressure, all with confidence intervals clear of zero.

### How much weight do teenagers lose?

Mean weight loss was 3.02 kg against placebo, far less than the figures adults see, partly because the pooled trials include older and weaker drugs and partly because follow-up is short. BMI percentile fell 7.24%, which is the more meaningful measure in a growing child.

### Is there a suicidality risk in adolescents?

No significant difference in suicidal ideation or behaviors was found. The authors note this rests on relatively short follow-up, which is a real limit rather than a reason to dismiss the finding.

### How long has this been studied in children?

Not long. The median treatment duration across all 18 trials was 0.51 years, with an interquartile range of three months to one year. A child starting at 13 might take these drugs for decades, and the evidence base is half a year deep.

### What about effects on growth and puberty?

Those need years of observation and the trials do not provide them. It is one of the strongest reasons for this prescribing to sit with a pediatric specialist who can monitor development over time.

## References

1. Kotecha P, Huang W, Yeh YY, et al. Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis. JAMA Pediatrics. 2025. PMID: 40952752. https://pubmed.ncbi.nlm.nih.gov/40952752/

---

Cite as: GLP Watchdog, Nora Bissett, "GLP-1 Drugs in Teenagers: What 18 Trials Show", published 2026-08-19, updated 2026-10-30. https://glpwatchdog.org/research/glp1-drugs-in-teenagers

Canonical HTML page: https://glpwatchdog.org/research/glp1-drugs-in-teenagers

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
